Dual-action drug produces shows promising results in neuroendocrine tumor trial
A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.
United States Jennifer Chan Jeffrey Meyerhardt Lily Ramsey Rectal Cancer Center At Dana Farber Dana Farber Cancer Institute
Source: news-medical.net